The US Food and Drug Administration has published for public review and comment two annexes to the International Conference on Harmonization’s (ICH) Q4B guideline, Evaluation of Pharmacopeial Texts for Use in the ICH Regions.
The US Food and Drug Administration has published for public review and comment two annexes to the International Conference on Harmonization’s (ICH) Q4B guideline, Evaluation of Pharmacopeial Texts for Use in the ICH Regions. The FDA published the drafts in the Federal Register on December 17, 2007.
Annex 2, Test for Extractable Volume of Parenteral Preparations General Chapter, states that the three official pharmacopeial texts on extractable volume from the European, Japanese, and US Pharmacopeias can be used interchangeably in the three ICH regions. In implementing this annex, the US FDA reserves the right to “request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.”
Annex 3, Test for Particulate Contamination: Subvisible Particles General Chapter, allows the three official pharmacopeial texts on particulate contamination be used interchangeably, provided that instrument calibration and system suitability measurements follow regional good manufacturing practices requirements.
Annex 3 also notes that the acceptance criteria are not interchangeable at the100-mL nominal volume, for which the Japanese criteria are more stringent.
Comments on the documents may be submitted until February 15, 2008.
Complete text of Annex 2
Complete text of Annex 3
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.